Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-996, 2005. ,
Epidemiologic and molecular prognostic review of glioblastoma, Cancer Epidemiol Biomarkers Prev, vol.23, pp.1985-1996, 2014. ,
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma, CA Cancer J Clin, vol.60, pp.166-193, 2010. ,
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer, Nature reviews Cancer, vol.8, pp.212-226, 2008. ,
Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies, Clin Cancer Res, vol.10, pp.184-190, 2004. ,
Van Noorden CJ. CD133+ and Nestin+ Glioma Stem-Like Cells Reside Around CD31+ Arterioles in Niches that Express SDF-1alpha, CXCR4, Osteopontin and Cathepsin K, J Histochem Cytochem, vol.63, pp.481-493, 2015. ,
Lentiviralmediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma, Hepatology, vol.48, pp.1834-1842, 2008. ,
The role of osteopontin in tumor progression and metastasis in breast cancer, Cancer Epidemiol Biomarkers Prev, vol.16, pp.1087-1097, 2007. ,
Upregulation of drug transporter expression by osteopontin in prostate cancer cells, Mol Pharmacol, vol.83, pp.968-977, 2013. ,
Expression of osteopontin in human glioma. Its correlation with the malignancy, Lab Invest, vol.72, pp.55-63, 1995. ,
Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis, Cancer Epidemiol Biomarkers Prev, vol.19, pp.1409-1422, 2010. ,
Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model, Int J Cancer, vol.126, pp.1797-1805, 2010. ,
Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo, Int J Cancer, vol.137, pp.1047-1057, 2015. ,
Beclin1-induced autophagy abrogates radioresistance of lung cancer cells by suppressing osteopontin, J Radiat Res, vol.53, pp.422-432, 2012. ,
Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells, Radiat Oncol, vol.5, p.82, 2010. ,
Osteopontin is a prognostic biomarker in non-small cell lung cancer, BMC Cancer, vol.13, p.540, 2013. ,
Role of osteopontin in tumour progression, Br J Cancer, vol.90, pp.1877-1881, 2004. ,
Serial plasma osteopontin levels have prognostic value in metastatic breast cancer, Clin Cancer Res, vol.12, pp.3337-3343, 2006. ,
Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients, Blood, vol.119, pp.5215-5220, 2012. ,
Osteopontin is a marker for cancer aggressiveness and patient survival, Br J Cancer, vol.103, pp.861-869, 2010. ,
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma, Cancer Res, vol.69, pp.4252-4259, 2009. ,
Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy, PLoS One, vol.5, p.10767, 2010. ,
Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines, Radiat Oncol, vol.10, p.167, 2015. ,
Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy, Radiother Oncol, vol.108, pp.535-540, 2013. ,
Overcoming obstacles to metastasis--defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells, J Cell Biochem, vol.56, pp.48-51, 1994. ,
Identification of therapeutic targets for glioblastoma by network analysis, Oncogene, vol.35, pp.608-620, 2016. ,
Glioblastoma-initiating cells: relationship with neural stem cells and the microenvironment, Cancers (Basel), vol.5, pp.1049-1071, 2013. ,
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.444, pp.756-760, 2006. ,
ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation, Clin Cancer Res, vol.19, pp.3189-3200, 2013. ,
Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma, Clin Cancer Res, vol.20, pp.1235-1248, 2014. ,
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered, FEBS J, vol.280, pp.5350-5370, 2013. ,
Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells, Cancer Biol Ther, vol.8, pp.730-738, 2009. ,
Regulation of CHK2 by DNA-dependent protein kinase, J Biol Chem, vol.280, pp.12041-12050, 2005. ,
Strategies to improve radiotherapy with targeted drugs, Nat Rev Cancer, vol.11, pp.239-253, 2011. ,
Anti-epidermal growth factor receptor strategies to enhance radiation action, Curr Med Chem Anticancer Agents, vol.3, pp.327-333, 2003. ,
CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive www.impactjournals.com/oncotarget oxygen species, focal adhesion kinase, and MMP-2, J Biol Chem, vol.283, pp.22513-22528, 2008. ,
CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression, Oral Oncol, vol.49, pp.306-313, 2013. ,
Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth, Cell Stem Cell, vol.14, pp.357-369, 2014. ,
Danish H and Neck Cancer Study G. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebocontrolled trial, Lancet Oncol, vol.6, pp.757-764, 2005. ,
Emerging biomarkers in glioblastoma, Cancers (Basel), vol.5, pp.1103-1119, 2013. ,
The somatic genomic landscape of glioblastoma, Cell, vol.155, pp.462-477, 2013. ,
NIH Image to ImageJ: 25 years of image analysis, Nature methods, vol.9, pp.671-675, 2012. ,
Clonogenic assay of cells in vitro, Nat Protoc, vol.1, pp.2315-2319, 2006. ,